Axsome Executive and Leadership Team

Herriot Tabuteau, the Chief Executive Officer at Axsome Therapeutics, directs the company's overarching strategy and vision. This leadership role involves guiding the development of novel therapies for central nervous system (CNS) conditions, focusing on areas with limited treatment options. Tabuteau ensures the company's therapeutic options, featuring novel mechanisms of action, fundamentally transform the approach to treating CNS conditions. Overseeing all executive functions, Herriot Tabuteau drives the organization's commitment to developing products that significantly improve patient lives and offer physicians expanded therapeutic choices. The Chief Executive Officer's strategic direction ensures alignment across all departments, fostering an environment of innovation and patient-centricity. This executive's focus remains on advancing the pipeline and achieving key regulatory milestones, solidifying Axsome Therapeutics' position in the biopharmaceutical sector.

Nicholas Pizzie, the Chief Financial Officer at Axsome Therapeutics, manages all financial operations and strategic financial planning. This executive oversees budgeting, forecasting, and capital allocation, ensuring the company's financial health supports its mission of developing novel CNS therapies. Pizzie's responsibilities include managing investor relations and securing funding necessary for research and development initiatives. The Chief Financial Officer plays a critical part in evaluating potential partnerships and acquisitions that align with Axsome Therapeutics' growth objectives. By maintaining rigorous financial controls and driving fiscal discipline, Nicholas Pizzie ensures resources are effectively deployed to advance therapeutic options for patients with limited treatment choices. This leadership position is vital for sustaining the company's long-term viability and its commitment to transforming CNS treatment paradigms.

Mark Jacobson, the Chief Operating Officer at Axsome Therapeutics, directs the company's operational infrastructure and execution of its strategic initiatives. This role involves overseeing the day-to-day business activities, ensuring efficient and effective development of novel therapies for central nervous system (CNS) conditions. Jacobson's purview includes managing manufacturing, supply chain logistics, and ensuring operational readiness for product launches. The Chief Operating Officer collaborates closely with research and development teams to streamline processes and accelerate the delivery of innovative treatments. By optimizing operational workflows, Mark Jacobson supports Axsome Therapeutics' commitment to providing meaningful improvements in the lives of patients and offering physicians new therapeutic options. This executive's leadership ensures the company operates with maximum efficiency, driving forward the transformation of CNS care.

Shelly Ogiste, the Senior President, Vice , Quality at Axsome Therapeutics, leads the company's comprehensive quality assurance and regulatory compliance functions. This critical role ensures that all therapeutic development and manufacturing processes adhere to the highest industry standards and regulatory requirements, particularly for novel therapies targeting central nervous system (CNS) conditions. Ogiste oversees the implementation and maintenance of robust quality management systems, guaranteeing the safety, efficacy, and reliability of Axsome Therapeutics' product pipeline. The Senior President, Vice , Quality is instrumental in fostering a culture of quality throughout the organization, supporting the mission to transform CNS treatment approaches. By maintaining stringent quality controls, Shelly Ogiste directly contributes to the company's ability to provide physicians and patients with trusted and effective therapeutic options.